Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Haematol. 2011 Oct;155(2):263-7. doi: 10.1111/j.1365-2141.2011.08827.x. Epub 2011 Aug 16.

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease.

Author information

  • 1Cincinnati Children's Hospital Medical Center, Hematology/Oncology, Cincinnati, OH 45220, USA. charles.quinn@cchmc.org

Abstract

Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3 years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8 h compared to placebo (P = 0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24 h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00530270.

© 2011 Blackwell Publishing Ltd.

PMID:
21848879
[PubMed - indexed for MEDLINE]
PMCID:
PMC3368951
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk